Huang, J., Chen, A., Jin, H., Liu, F., Hei, G., Teng, Z., Xiao, J., Wu, R., Zhao, J., Davis, J. M., Shao, P., & Smith, R. C. (2025). Efficacy and Safety of Sulforaphane Added to Antipsychotics for the Treatment of Negative Symptoms of Schizophrenia. The Journal of Clinical Psychiatry, 86(1). https://doi.org/10.4088/jcp.24m15272

Lieberman, J. A., Mendelsohn, A., Goldberg, T. E., & Emsley, R. (2025). Preventing disease progression in schizophrenia: What are we waiting for. Journal of Psychiatric Research, 181, 716–727. https://doi.org/10.1016/j.jpsychires.2024.12.042

Sourander, A., Silwal, S., Surcel, H.-M., Hinkka-Yli-Salomäki, S., Cheslack-Postava, K., Upadhyaya, S., McKeague, I. W., & Brown, A. S. (2025). Maternal vitamin B12 during pregnancy and schizophrenia in offspring. Psychiatry Research, 344, 116284. https://doi.org/10.1016/j.psychres.2024.116284

Javitt, D. C. (2024). Mismatch Negativity (MMN) as a Pharmacodynamic/Response Biomarker for NMDA Receptor and Excitatory/Inhibitory Imbalance-Targeted Treatments in Schizophrenia. Neurophysiologic Biomarkers in Neuropsychiatric Disorders, 411–451. https://doi.org/10.1007/978-3-031-69491-2_15

Kantrowitz, J. T., & Javitt, D. C. (2024). The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry. Neurophysiologic Biomarkers in Neuropsychiatric Disorders, 801–828. https://doi.org/10.1007/978-3-031-69491-2_26

Gonzales, L., Saperstein, A. M., Qian, M., Gorecki, A., & Medalia, A. (2024). Psychiatric and functional correlates of stigma associated with cognitive impairment in schizophrenia. Psychiatry Research, 342, 116233. https://doi.org/10.1016/j.psychres.2024.116233

Sourander, A., Upadhyaya, S., Surcel, H.-M., Hinkka-Yli-Salomäki, S., Cheslack-Postava, K., Silwal, S., McKeague, I. W., & Brown, A. S. (2024). Maternal vitamin D levels during pregnancy and offspring schizophrenia. Schizophrenia Research, 270, 289–294. https://doi.org/10.1016/j.schres.2024.06.039

van der Ven, E., Olino, T. M., Diehl, K., Nuñez, S. M., Thayer, G., Bridgwater, M. A., Ereshefsky, S., Musket, C., Lincoln, S. H., Rogers, R. T., Klaunig, M. J., Soohoo, E., DeVylder, J. E., Grattan, R. E., Schiffman, J., Ellman, L. M., Niendam, T. A., & Anglin, D. M. (2024). Ethnoracial Risk Variation Across the Psychosis Continuum in the US. JAMA Psychiatry, 81(5), 447. https://doi.org/10.1001/jamapsychiatry.2023.5497

Amsalem, D., Jankowski, S. E., Pagdon, S., Smith, S., Yang, L. H., Valeri, L., Markowitz, J. C., Lewis-Fernández, R., & Dixon, L. B. (2024). “It’s Tough to Be a Black Man with Schizophrenia”: Randomized Controlled Trial of a Brief Video Intervention to Reduce Public Stigma. Schizophrenia Bulletin, 50(3), 695–704. https://doi.org/10.1093/schbul/sbae019

Gao, Y. N., Wang, R., Gu, G., Chung, R., & Olfson, M. (2024). Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders. Schizophrenia Research, 267, 165–172. https://doi.org/10.1016/j.schres.2024.03.034

Ray, W. A., Fuchs, D. C., Olfson, M., Patrick, S. W., Stein, C. M., Murray, K. T., Daugherty, J., & Cooper, W. O. (2024). Antipsychotic Medications and Mortality in Children and Young Adults. JAMA Psychiatry, 81(3), 260. https://doi.org/10.1001/jamapsychiatry.2023.4573

Ratanatharathorn, A., Quan, L., Koenen, K. C., Chibnik, L. B., Weisskopf, M. G., Slopen, N., & Roberts, A. L. (2024). Polygenic risk for major depression, attention deficit hyperactivity disorder, neuroticism, and schizophrenia are correlated with experience of intimate partner violence. Translational Psychiatry, 14(1). https://doi.org/10.1038/s41398-024-02814-1

Gonzales, L., Kois, L. E., Mandracchia, F., Dhillon, A., & Purcell, A. (2024). Community member attitudes and understanding of “serious mental illness”: A mixed-method study. Psychiatric Rehabilitation Journal, 47(2), 150–156. https://doi.org/10.1037/prj0000598

Andreo-Jover, J., Wootton, O., Fernández-Jiménez, E., Muñoz-Sanjosé, A., Mediavilla, R., Bravo-Ortiz, M. F., Susser, E., Gur, R. C., & Stein, D. J. (2024). Adverse childhood experiences and cognition: A cross-sectional study in Xhosa people living with schizophrenia and matched medical controls. Comprehensive Psychiatry, 130, 152459. https://doi.org/10.1016/j.comppsych.2024.152459

Lawrence, R. E., & Bernstein, A. (2024). Schizophrenia and Emergency Medicine. Emergency Medicine Clinics of North America, 42(1), 93–104. https://doi.org/10.1016/j.emc.2023.06.012

Christofalos, A. L., Laks, M., Wolfer, S., Dias, E. C., Javitt, D. C., & Sheridan, H. (2024). Lower-level oculomotor deficits in schizophrenia during multi-line reading: Evidence from return-sweeps. Quarterly Journal of Experimental Psychology, 77(7), 1533–1543. https://doi.org/10.1177/17470218231220752

Lawrence, R. E., & Appelbaum, P. S. (2024). Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks. Schizophrenia Research, 264, 372–377. https://doi.org/10.1016/j.schres.2024.01.018

Martínez, A., Gaspar, P. A., Bermudez, D. H., Belen Aburto-Ponce, M., Beggel, O., & Javitt, D. C. (2024). Disrupted third visual pathway function in schizophrenia: Evidence from real and implied motion processing. NeuroImage: Clinical, 41, 103570. https://doi.org/10.1016/j.nicl.2024.103570

Rummell, B. P., Bikas, S., Babl, S. S., Gogos, J. A., & Sigurdsson, T. (2023). Altered corollary discharge signaling in the auditory cortex of a mouse model of schizophrenia predisposition. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42964-2

Sehatpour, P., Kreither, J., Lopez-Calderon, J., Shastry, A. M., De Baun, H. M., Martinez, A., & Javitt, D. C. (2023). Network-level mechanisms underlying effects of transcranial direct current stimulation (tDCS) on visuomotor learning in schizophrenia. Translational Psychiatry, 13(1). https://doi.org/10.1038/s41398-023-02656-3

Saperstein, A. M., Subhan, B. A., Golub, J. S., & Medalia, A. (2024). Hearing Loss in Older People With Schizophrenia: Audiologic Characteristics and Association With Psychosocial Functioning. The American Journal of Geriatric Psychiatry, 32(4), 489–496. https://doi.org/10.1016/j.jagp.2023.11.002

Moorthy, T., Nguyen, H., Chen, Y., Austin, J., Smoller, J. W., Hercher, L., & Sabatello, M. (2023). How do experts in psychiatric genetics view the clinical utility of polygenic risk scores for schizophrenia? American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 192(7–8), 161–170. Portico. https://doi.org/10.1002/ajmg.b.32939

Wootton, O., Shadrin, A. A., Mohn, C., Susser, E., Ramesar, R., Gur, R. C., Andreassen, O. A., Stein, D. J., & Dalvie, S. (2023). Genome-wide association study in 404,302 individuals identifies 7 significant loci for reaction time variability. Molecular Psychiatry, 28(9), 4011–4019. https://doi.org/10.1038/s41380-023-02292-9

Wootton, O., King, A., Moy, K., Stein, D. J., & Susser, E. S. (2023). Disability benefits protect against lost income for South Africans living with Schizophrenia. Social Psychiatry and Psychiatric Epidemiology, 59(7), 1279–1283. https://doi.org/10.1007/s00127-023-02577-y

Birkenæs, V., Refsum Bakken, N., Frei, E., Jaholkowski, P., Smeland, O. B., Tesfaye, M., Agartz, I., Susser, E., Bresnahan, M., Røysamb, E., Nordbø Jørgensen, K., Nesvåg, R., Havdahl, A., Andreassen, O. A., & Elken Sønderby, I. (2023). Psychometric Properties and Diagnostic Associations of the Short-Form Community Assessment of Psychic Experiences in a Population-Based Sample of 29 021 Adult Men. Schizophrenia Bulletin, 49(5), 1229–1238. https://doi.org/10.1093/schbul/sbad074

Amsalem, D., Rogers, R. T., Stroup, T. S., Dixon, L., & Pope, L. G. (2023). Self-stigma among people with serious mental illnesses: The use of focus groups to inform the development of a brief video intervention. Psychiatric Rehabilitation Journal, 46(3), 243–249. https://doi.org/10.1037/prj0000570

Yoshida, K., Marshe, V. S., Elsheikh, S. S. M., Maciukiewicz, M., Tiwari, A. K., Brandl, E. J., Lieberman, J. A., Meltzer, H. Y., Kennedy, J. L., & Müller, D. J. (2023). Polygenic risk scores analyses of psychiatric and metabolic traits with antipsychotic-induced weight gain in schizophrenia: an exploratory study. The Pharmacogenomics Journal, 23(5), 119–126. https://doi.org/10.1038/s41397-023-00305-y

Thomas, M. D., Vittinghoff, E., Koester, K. A., Dahiya, P., Riano, N. S., Cournos, F., Dawson, L., Olfson, M., Pinals, D. A., Crystal, S., Walkup, J., Shade, S., Mangurian, C., & Arnold, E. A. (2023). Examining the Impact of State-Level Factors on HIV Testing for Medicaid Enrollees With Schizophrenia. JAIDS Journal of Acquired Immune Deficiency Syndromes, 94(1), 18–27. https://doi.org/10.1097/qai.0000000000003225

Sehatpour, P., Iosifescu, D. V., De Baun, H. M., Shope, C., Mayer, M. R., Gangwisch, J., Dias, E., Sobeih, T., Choo, T.-H., Wall, M. M., Medalia, A., Saperstein, A. M., Kegeles, L. S., Girgis, R. R., Carlson, M., & Kantrowitz, J. T. (2023). Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine. Biological Psychiatry, 94(2), 164–173. https://doi.org/10.1016/j.biopsych.2023.01.015

Jester, D. J., Thomas, M. L., Sturm, E. T., Harvey, P. D., Keshavan, M., Davis, B. J., Saxena, S., Tampi, R., Leutwyler, H., Compton, M. T., Palmer, B. W., & Jeste, D. V. (2023). Review of Major Social Determinants of Health in Schizophrenia-Spectrum Psychotic Disorders: I. Clinical Outcomes. Schizophrenia Bulletin, 49(4), 837–850. https://doi.org/10.1093/schbul/sbad023

Sturm, E. T., Thomas, M. L., Sares, A. G., Dave, S., Baron, D., Compton, M. T., Palmer, B. W., Jester, D. J., & Jeste, D. V. (2023). Review of Major Social Determinants of Health in Schizophrenia-Spectrum Disorders: II. Assessments. Schizophrenia Bulletin, 49(4), 851–866. https://doi.org/10.1093/schbul/sbad024

Cheslack-Postava, K., Rantakokko, P., Surcel, H.-M., Hinkka-Yli-Salomäki, S., Laitinen, J., Upadhyaya, S., McKeague, I. W., Sourander, A., & Brown, A. S. (2023). Prenatal organochlorine pollutant exposure and risk of schizophrenia in a national birth cohort. NeuroToxicology, 97, 47–52. https://doi.org/10.1016/j.neuro.2023.05.010

Walkup, J., Thomas, M. D., Vittinghoff, E., Hermida, R., Crystal, S., Arnold, E. A., Dahiya, P., Olfson, M., Cournos, F., Dawson, L., Dilley, J., Bazazi, A., & Mangurian, C. (2023). Characteristics and Trends in HIV Testing Among Medicaid Enrollees Diagnosed as Having Schizophrenia. Psychiatric Services, 74(7), 709–717. https://doi.org/10.1176/appi.ps.20220311

Saperstein, A. M., Meyler, S., Golub, J. S., & Medalia, A. (2023). Correlates of hearing loss among adults with schizophrenia. Schizophrenia Research, 257, 1–4. https://doi.org/10.1016/j.schres.2023.05.014

Kantrowitz, J. T., Correll, C. U., Jain, R., & Cutler, A. J. (2023). New Developments in the Treatment of Schizophrenia: An Expert Roundtable. International Journal of Neuropsychopharmacology, 26(5), 322–330. https://doi.org/10.1093/ijnp/pyad011

Medalia, A., Saperstein, A., Javitt, D. C., Qian, M., Meyler, S., & Styke, S. (2023). Feasibility and clinical utility of using the tone matching test for assessment of early auditory processing in schizophrenia. Psychiatry Research, 323, 115152. https://doi.org/10.1016/j.psychres.2023.115152

Hwong, A. R., Vittinghoff, E., Thomas, M., Hermida, R., Walkup, J., Crystal, S., Olfson, M., & Mangurian, C. (2023). Breast Cancer Screening Rates Among Medicaid Beneficiaries With Schizophrenia. Psychiatric Services, 74(5), 497–504. https://doi.org/10.1176/appi.ps.20220163

Hogoboom, A., Rouch, M., Lauerman, D., Pauselli, L., & Compton, M. T. (2023). Initial evidence of vowel space reduction in a subset of individuals with schizophrenia. Schizophrenia Research, 255, 158–164. https://doi.org/10.1016/j.schres.2023.03.026

Dondé, C., Kantrowitz, J. T., Medalia, A., Saperstein, A. M., Balla, A., Sehatpour, P., Martinez, A., O’Connell, M. N., & Javitt, D. C. (2023). Early auditory processing dysfunction in schizophrenia: Mechanisms and implications. Neuroscience & Biobehavioral Reviews, 148, 105098. https://doi.org/10.1016/j.neubiorev.2023.105098

Saperstein, A. M., Meyler, S., & Medalia, A. (2023). Hearing Loss Among People With Schizophrenia: Implications for Clinical Practice. Psychiatric Services, 74(5), 543–546. https://doi.org/10.1176/appi.ps.20220226

Ku, B. S., Walker, E. F., Druss, B. G., Murray, C. R., & Compton, M. T. (2023). Residential instability during adolescence predicts earlier age at onset of psychosis: The moderating role of extraversion. Early Intervention in Psychiatry, 17(5), 527–531. Portico. https://doi.org/10.1111/eip.13375

Baygin, M., Barua, P. D., Chakraborty, S., Tuncer, I., Dogan, S., Palmer, E., Tuncer, T., Kamath, A. P., Ciaccio, E. J., & Acharya, U. R. (2023). CCPNet136: automated detection of schizophrenia using carbon chain pattern and iterative TQWT technique with EEG signals. Physiological Measurement, 44(3), 035008. https://doi.org/10.1088/1361-6579/acb03c

Alkelai, A., Greenbaum, L., Shohat, S., Povysil, G., Malakar, A., Ren, Z., Motelow, J. E., Schechter, T., Draiman, B., Chitrit-Raveh, E., Hughes, D., Jobanputra, V., Shifman, S., Goldstein, D. B., & Kohn, Y. (2023). Genetic insights into childhood-onset schizophrenia: The yield of clinical exome sequencing. Schizophrenia Research, 252, 138–145. https://doi.org/10.1016/j.schres.2022.12.033

Wootton, O., Dalvie, S., Susser, E., Gur, R. C., & Stein, D. J. (2023). Within-individual variability in cognitive performance in schizophrenia: A narrative review of the key literature and proposed research agenda. Schizophrenia Research, 252, 329–334. https://doi.org/10.1016/j.schres.2023.01.028

Herrera, S. N., Sarac, C., Phili, A., Gorman, J., Martin, L., Lyallpuri, R., Dobbs, M. F., DeLuca, J. S., Mueser, K. T., Wyka, K. E., Yang, L. H., Landa, Y., & Corcoran, C. M. (2023). Psychoeducation for individuals at clinical high risk for psychosis: A scoping review. Schizophrenia Research, 252, 148–158. https://doi.org/10.1016/j.schres.2023.01.008

Javitt, D. C. (2023). Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment. Annual Review of Pharmacology and Toxicology, 63(1), 119–141. https://doi.org/10.1146/annurev-pharmtox-051921-093250

Qi, W., Marx, J., Zingman, M., Li, Y., Petkova, E., Blessing, E., Ardekani, B., Sakalli Kani, A., Cather, C., Freudenreich, O., Holt, D., Zhao, J., Wang, J., & Goff, D. C. (2022). Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode Schizophrenia. Schizophrenia Bulletin, 49(1), 34–42. https://doi.org/10.1093/schbul/sbac043

Bareis, N., Olfson, M., Gerhard, T., Rolin, S., & Stroup, T. S. (2023). Means of suicide among adults with schizophrenia across the life span. Schizophrenia Research, 251, 82–90. https://doi.org/10.1016/j.schres.2022.12.004

Rabadan, M. A., De La Cruz, E. D., Rao, S. B., Chen, Y., Gong, C., Crabtree, G., Xu, B., Markx, S., Gogos, J. A., Yuste, R., & Tomer, R. (2022). An in vitro model of neuronal ensembles. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-31073-1